LAURA H. CYPHERS

This Viewpoint discusses the unfairness of current CAR T-cell therapy allocation practices and offers alternative methods to more fairly allocate therapy.
Source: JAMA Online First

Authors of this Viewpoint discuss the recent “pause” of the NIH Common Fund’s research program that was designed to study the communication of science and the possible detrimental effect of not addressing scientific misinformation and disinformation.
Source: JAMA Online First

This JAMA Patient Page describes the problem of polypharmacy and its consequences, and how deprescribing can reduce polypharmacy.
Source: JAMA Online First

In this narrative medicine essay, a palliative medicine physician learns firsthand how to listen to her mother’s end-of-life wishes amid the waves of loss and the noise of the treatment options being offered.
Source: JAMA Online First

This Special Communication used data from the US Food and Drug Administration to analyze how manufacturers of brand-name glucagon-like peptide 1 (GLP-1) receptor agonists have used patent and regulatory systems to extend periods of market exclusivity.
Source: JAMA Online First

This Viewpoint summarizes inefficiencies in the 340B program and provides suggestions for equitable reform that will potentially benefit patients.
Source: JAMA Online First

A nonsmoking patient with gastroesophageal reflux disease and Raynaud disease had 4 weeks of dysphagia and a 4.54-kg weight loss over 3 months, cough productive of yellow sputum, and dyspnea on exertion. White blood cell count and creatine kinase and aldolase levels were elevated; antinuclear antibody assay findings were positive; and chest CT showed bibasilar pulmonary consolidations and ground glass opacities. What is the diagnosis and what would you do next?
Source: JAMA Online First

Following the rapidly evolving use of artificial intelligence (AI) tools such as large language models (LLMs) and generative chatbots, JAMA and the JAMA Network journals released guidance on the responsible use of these tools by authors and researchers in scholarly publishing. These policies preclude the inclusion of nonhuman AI tools as authors and require the transparent reporting of use of such tools in preparing manuscripts and other content and when used in research submitted for publication. In addition, submission and publication of clinical images created by AI tools is discouraged, unless part of formal research design or methods. In all such cases, authors must take responsibility for the integrity of the content generated by these models and tools.
Source: JAMA Online First

This Viewpoint discusses potential benefits and unintended consequences of out-of-pocket cost caps in Medicare and the employer-sponsored health insurance market and provides suggested policy opportunities to address shortcomings.
Source: JAMA Online First

Nirsevimab-alip, marketed as Beyfortus by AstraZeneca, has received US Food and Drug Administration authorization for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants and children up to 2 years old.
Source: JAMA Online First